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ABSTRACT
Background: The past decade, medical technology assessment focused on
cost-effectiveness analysis, yet there is an increasing need to consider
equity implications of health interventions as well. This article addresses
three equity–efﬁciency trade-off methods proposed in the literature. More-
over, it demonstrates their impact on cost-effectiveness analyses in current
breast cancer control options for women of different age groups.
Methods: We adapted an existing breast cancer model to estimate cost-
effectiveness and equity effects of breast cancer interventions. We applied
three methods to quantify the equity–efﬁciency trade-offs: 1) targeting
speciﬁc groups, comparing disparities at baseline and in different interven-
tion scenarios; 2) equity weighting, valuing low and high health gains
differently; and 3) multicriteria decision analysis, weighing multiple equity
and efﬁciency criteria. We compared the resulting composite league tables
of all approaches.
Results: The approaches show that a comprehensive breast cancer
program, including screening, for women below 75 years of age was most
attractive in both the group targeting approach and the equity weighting
approach. Such control programs would reduce disparities with 56% and
at €1908 per equity quality-adjusted life-year gained. In the multicriteria
approach, a comprehensive treatment program for women below 75 years
of age and treatment in stage III breast cancer were most attractive, with
both an 82% selection probability, followed by screening programs for the
two age groups.
Conclusion: In the three equity weighing approaches, targeting women
below 75 years of age was more cost-effective and led to more equitable
distributions of health. This likely is similar in other fatal diseases with
similar age distributions. The approaches may lead to different outcomes
in nonfatal disease.
Keywords: breast cancer, equity–efﬁciency trade-off, health economics
methods, Markov model.
Introduction
The distribution of the disease burden [1,2] and treatment ben-
eﬁts [3,4] are frequently an area of health economics research. In
breast cancer, control studies reveal differences in disease burden
by race [2], urbanization [5], socioeconomic status [6], and insur-
ance status [7]. These studies typically report disparities in inci-
dence, prevalence, stage distribution, and disease mortality. In
some studies, differences in quality-adjusted life expectancy are
calculated [8]. One may distinguish three ways of equity report-
ing [9].
First, one may observe differences in health outcomes, such as
life expectancy, quality of life, and incidence of a condition.
Second, disparities may be reported in the provision of health
care with those with a more severe condition receiving less, i.e.,
vertical equity. Third, inequities may be related to dissimilar use
of health care for individuals with the same health, i.e., horizon-
tal equity [9]. These three types of equity are interrelated, as
utilization of health care is related to health outcomes, and both
are related to difference in access. In all cases, inequalities may be
reduced through the provision of additional health care to under-
privileged groups, for example, by differential reimbursement of
health packages [10].
Descriptive and distinct information about health disparities
and cost-effectiveness estimates in relation to health interventions
may be available and may give insight. Yet, due to the descriptive
nature, its use in health policy, addressing equity and efﬁciency, is
limited. Such a broad approach to evidence-based priority setting
in health programming would use efﬁciency information on
available strategies, as well as their potential for reducing exist-
ing disparities. Without this, reduction of inequalities as a policy
goal remains a matter of intuition and debate, rather than of
systematic evaluation. If so, still, interventions may have differ-
ential effects on the distribution of health depending on the way
health inequalities are actually deﬁned, measured, and addressed.
Methodological studies on the use of equity considerations in
cost-effectiveness analysis and its effect on health inequalities are
reported [11–15]. Nevertheless, comparisons of the impact of
these methods in economic evaluation have, so far, not been
done, and any application in breast cancer control is absent. We
distinguished three different methods that can be potentially
beneﬁcial in priority setting: targeting speciﬁc groups, equity
weighting [13], and multicriteria decision analysis [11,16].
The aim of the article is to show the potential and the impact
of these approaches in the use of cost-effectiveness analysis, e.g.,
by government agencies responsible for the selection of health
beneﬁt packages. Such processes may have yet to become more
explicit, transparent, and thorough if equity implications are to
be considered similarly as and parallel to cost-effectiveness analy-
ses. Our perspective is societal and governmental, given the
nature of any operational equity–efﬁciency approach.
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We explain three approaches in the method section and relate
them to the underlying theory. Subsequently, we demonstrate
their application in cost-effectiveness analyses, aiming at a rank
order of optional interventions. We apply the equity-
incorporating approaches for breast cancer control evaluations
using an existing breast cancer life table model [17], addressing
the existing controversy in breast cancer control options by age
groups. Differentiating breast cancer control options by age is
subject to debate [18–20].
Methods
We ﬁrst describe three equitability approaches; subsequently, we
summarize the use and application of the existing World Health
Organization (WHO) breast cancer model and the combined
equity and cost-effectiveness analysis.
Equity Approaches
Targeting speciﬁc groups. The ﬁrst method we identiﬁed for the
integration of distributive and economical impact of health inter-
ventions is simply targeting speciﬁc groups. This method shows
how disparities between groups in breast cancer burden can be
reduced through interventions in speciﬁc population subgroups,
e.g., on the basis of insurance status [21]. The ﬁrst step in the
analysis is identical to the measurement of systematic differences
by subgroups, usually deﬁned by an indicator of social economic
status. The second step involves selecting an intervention which
addresses the difference between those speciﬁc subgroups. This
means that it is necessary to determine what causes these differ-
ences in the ﬁrst place and in which way they can best be
diminished. One or more scenarios can then be constructed in
which the targeted group of patients receives the intervention and
the remaining group receives the usual level of care. The analyses
show the potential improvement in health outcomes of groups of
patients both in absolute (increase in health) and relative (reduc-
tion of inequalities) terms.
Equity weighing. Equity weighting [13] is based on the concept
of the rank-dependent quality-adjusted life-year (QALY) model
[12]. This method aggregates QALY gains from health interven-
tions over a person’s lifetime. In traditional health utility analy-
ses, aggregation is straightforward, assigning equal valuation to
each QALY gained. Nevertheless, policymakers may want to
discriminate between various subgroups when choosing health
interventions and may want to give more weight to health gains
achieved in relative worse-off groups. Equity weighting quantiﬁes
these preferences by assessing the rank of the beneﬁciaries in the
distribution of health. In this approach, the valuation of QALYs
is nonlinear, which makes it possible to assign extra weight to the
worst-off. The social value of a QALY proﬁle (i.e., the distribu-
tion of health) is then given by:
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i
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=
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where pi is the weight given to the QALY score q for individual
i. The nonlinearity is shown by the function U(qi) instead of qi. In
this approach, the objective is to maximize Equation 1 instead of
health as described in Equation 2 [13]:
qi
i
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(2)
We assess the values of qi in different scenarios and com-
pare results with and without equity weighting, using both
Equations 1 and 2. We use values of equity weights from the
Dutch setting [13].
Multicriteria decision analysis. Multicriteria decision analysis
reﬂects societal preferences for a number of characteristics of
health programs in addition to cost-effectiveness, such as severity
of the disease and the average age of the targeted population
[11]. The full set of criteria [16,22,23] describes the most impor-
tant aspects of a health intervention. The preferences of society
are then measured through a conjoint analysis. First, respondents
are simultaneously presented with two health interventions
described by the full set of criteria, i.e., a proﬁle. From these two
interventions, they are asked to pick the most attractive one. A
statistical analysis is then used to determine the relative impor-
tance of each criterion, reﬂected by a beta coefﬁcient. Using these
coefﬁcients, the attractiveness of every intervention described by
the full set of criteria can be calculated. The attractiveness of each
proﬁle is measured as the probability of selection. Using the
probability of selection, different interventions can be ranked in
a composite league table.
We will use criteria and coefﬁcients from multicriteria inves-
tigation among Health Technology Assessment (HTA) policy-
makers [23]. The general regression equation is:
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where b0 is a constant, k indicates one of the eight dummy
variables (i.e., six criteria of which two have three levels instead
of two), and Xk indicates the score of the scenario on the dummy
variable (i.e., either 0 or 1).
As discussed above, all three approaches deal with costs,
effects, and equity in a different way. Some approaches describe
equity implications more thoroughly than others. Although some
use all cost-effectiveness data, others limit themselves in that
regard. Yet all of them ultimately have the same goal: providing
an informed equity–efﬁciency trade-off by ordering health inter-
ventions in a composite league table. Table 1 summarizes the way
the three approaches incorporate the different aspects of health
interventions. For illustrative purposes, a characterization of tra-
ditional health technology assessment is given as well.
Breast Cancer Model
We adapted an existing, standardized WHO method to arrive at
comparative estimates in a broad cost-effective analysis to a
multitude of interventions that is now under the name of the
Choosing Interventions That Are Cost-Effective (CHOICE)
program [27]. The existing breast cancer model based on this
method [17] was adapted in such a way that it is suitable to
incorporate the three equity approaches. The breast cancer
model distinguishes four breast cancer stages deﬁned according
to the guideline deﬁnitions of the American Joint Committee on
Cancer [24]. Breast cancer stages discern with regard to inci-
dence, prevalence, case–fatality ratio, and health state valuation.
We used age-speciﬁc epidemiological data for the European
region from the Global Burden of Disease Studies [25]. Using
age-adjusted data by breast cancer stage [17], we computed age
and stage-speciﬁc prevalence, incidence, and mortality rates to
estimate survival by disease stage. The age-adjusted estimates are
provided in Table 2.
Cost estimates were also derived from the original study by
Groot et al. We updated the cost prices to reﬂect 2007 prices by
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using a price index of 116.3 (2000 = 100) [26]. We included
patient costs based on treatment, follow-up, diagnostic workup
of healthy women, screening, and false positive cases. Table 2
lists the associated cost. Furthermore, we assumed equal access
to care and equal effectiveness of care for each age group in the
existing situation.
First, we constructed a baseline, counterfactual scenario for all
patients, irrespective of breast cancer stage or age, in the absence
of treatment [17,27]. In the intervention scenarios, we imple-
mented different sets of treatment in which the stage-speciﬁc
case–fatalities and/or distribution of incident breast cancer cases
were improved for either of the two age groups. The effects of the
intervention scenarioswere calculated over a standard time period
for the whole of the breast cancer population. The intervention
scenarios also differed with respect to which patient groups were
treated, deﬁned by the stage of breast cancer and age. The groups
were analyzed separately, and arewomen aged 75 or less and those
over 75. In summary, we assessed 12 scenarios: six interventions
(the treatment of individual breast cancer stages I, II, III, or IV; the
treatment of all stages; the treatment of all stages plus mammog-
raphy screening) for two groups of women separately, i.e., those
below 75 years of age and those of 75 years and over.
We ﬁrst applied these scenarios in the simple reporting
approach to demonstrate the potential for diminishing health
inequalities between the two age groups. Second, we used equity
weighting to revalue the gains of interventions in the two groups.
Third, we applied multicriteria decision analysis to breast cancer
treatment and screening for the different age groups. Each
approach provided a different league table of the investigated
health interventions that consider different breast cancer inter-
ventions and target groups.
Combined Equity and Efﬁciency Analysis
Targeting speciﬁc groups. We applied the breast cancer model to
the EuroA zone of the WHO Global Burden of Disease Regions,
commonly used for WHO CHOICE analyses. Analyses were
performed separately for women below 75 years and those 75
years and over. As prevalent cases are inherently untreated at t = 0
and are more numerous in the higher age group, we only include
incident cases. We calculated outcomes for both age groups
without any treatment. To ensure all health beneﬁtswere included,
the time horizon was 100 years. To correct for the women’s lower
life expectancy in higher age groups, we also included past life-
years, which were assumed to be spent in good health.
In the base-case scenario, we calculated the average unad-
justed and QALYs, and determined the initial health disparity
between both groups. Subsequently, we introduced the six inter-
ventions one by one for each group separately and monitored the
changes in health disparities. In other words, in each step and for
each combination of interventions, we computed the difference in
health between women below 75 years and those 75 and over.
Equity weighing. Equity preference weights were derived from
preferences of the general population of The Netherlands by
Bleichrodt et al. [13]. The weights were differentiated by age and
Table 1 Outline of the three approaches including equity in cost-effectiveness analysis
Approach Costs Effect Equity implication League table based on
Traditional cost-effectiveness
analysis
Included Difference in health-adjusted
life-years
Not applied ICER
Group-targeted intervention Not considered Difference in DALE by age group
per scenario
Absolute and relative reduction of health
disparities between groups
Percentage reduction
group differences
Equity weighting Included Equity weights times delta health
years (i.e., EQALY)
Health beneﬁts weighted higher for diseases
with larger impact on lifetime health
E-ICER
Multicriteria decision analysis Cost and effects categorized as attributes Equity concept is captured in three attributes Probability of selection
DALE, disability-adjusted life expectancy; (E-)ICER, (equity-adjusted) incremental cost-effectiveness ratio; (E)QALY, (equity and) quality-adjusted life-year.
Table 2 Breast cancer model inputs
Stage I Stage II Stage III Stage IV All
Disease data
Stage distribution at diagnosis
Without screening 0.09440 0.14170 0.57970 0.18420
With screening 0.49000 0.37440 0.08610 0.04950
Stage-speciﬁc mortality
Without treatment 0.02000 0.06286 0.15000 0.30000
With treatment 0.00638 0.04266 0.09336 0.27500
Background mortality 0.0102
Prevalence rate 0.0081
Incidence rate 0.0011
Female population 8,002,084
Costs (€)
Treatment 6,292 6,292 7,066 3,387
Diagnosis
Breast cancer patient 361
Healthy woman 86
Follow-up years 1–5 154
Follow-up years 6–10 111
Mammography 43
False positive screening
Diagnosis 85
Biopsy 50
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stage of breast cancer at onset. Health effects were ﬁrst calculated
as the number of unweighted health years gained per treated
woman and subsequently weighted, applying the weights found
in the Bleichrodt et al. study. These weighted health years are the
multiplication of the total health effect for breast cancer patients
at a certain age with the corresponding equity weight. We refer to
this result as equity and QALY (EQALYs).
Multicriteria decision analysis. In the multicriteria approach,
we valued health interventions using the different characteristics
of the interventions and the patient groups they are intended for.
An index of the characteristics of the breast cancer intervention
is used, from published discrete choice experiments [22]. We
characterized the breast cancer interventions according to the
descriptive criteria used: severity of disease, number of potential
beneﬁciaries, age of target group, individual health beneﬁts,
poverty reduction, and cost-effectiveness. All of these variables
have either two or three ordinal levels. The coefﬁcients for the
levels of the attributes were derived from a study with North
American policymakers and HTA experts [23,28]. Through
application of the coefﬁcients for the indexed levels for each
intervention in Equation 3, an overall probability was calculated,
reﬂecting the relative attractiveness of the scenario.
Comparing our ﬁndings, we compared all 12 scenarios (six
interventions for two different groups) for all three approaches in
a new, composite league table in which the rank order was
determined by the different outcome measures in each equity
approach. Hence, the ranking resulting from the traditional cost-
effectiveness analysis was determined by the cost-effectiveness
ratios (CERs); the group targeting ranking depended on the
relative reduction in the health gap (largest reduction preferred);
the CER based on EQALYs was used to rank the scenarios in the
equity weighting approach; and the probability of selection was
used to order the results of the multicriteria decision analysis.
Results
In Table 3, the effects of breast cancer intervention on the dis-
parities between the two age groups are presented. In the initial
situation, without any breast cancer treatment for either group,
the higher age group lives 4.87 lifetime QALYs longer (i.e., the
difference in past and future health). Treating the group of breast
cancer patients below 75 years of age reduces disparities with a
maximum of 56% (screening and treatment of all breast cancer
stages); treating the group of women over 80 years of age would
increase the difference between the groups up to 6.55 lifetime
QALYs, which is an increase of 34.5%.
The results per patient of both the traditional cost-
effectiveness analysis and the cost-effectiveness analysis with
equity weighting are presented in Table 4. The largest costs and
Table 3 Health gap and changes in health when targeting two age groups
Stage treatment of women over 75 years
None Stage I Stage II Stage III Stage IV All stages
All stages
plus screening
Stage treatment of women
under 75 years
None QALY gap -4.87 -4.91 -4.93 -5.23 -4.89 -5.36 -6.54
Absolute reduction 0.00 0.04 0.06 0.36 0.02 0.49 1.68
Relative reduction (%) 0.0 -0.9 -1.3 -7.5 -0.5 -10.1 -34.5
Stage I QALY gap -4.83 -4.88 -4.89 -5.20 -4.86 -5.32 -6.51
Absolute reduction -0.03 0.01 0.03 0.33 -0.01 0.46 1.64
Relative reduction (%) 0.7 -0.2 -0.6 -6.8 0.2 -9.4 -33.8
Stage II QALY gap -4.81 -4.85 -4.87 -5.17 -4.83 -5.30 -6.49
Absolute reduction -0.06 -0.01 0.00 0.31 -0.03 0.43 1.62
Relative reduction (%) 1.2 0.3 -0.1 -6.3 0.7 -8.9 -33.3
Stage III QALY gap -4.44 -4.49 -4.50 -4.81 -4.47 -4.93 -6.12
Absolute reduction -0.42 -0.38 -0.36 -0.06 -0.40 0.07 1.25
Relative reduction (%) 8.7 7.8 7.4 1.3 8.3 -1.4 -25.8
Stage IV QALY gap -4.82 -4.87 -4.88 -5.19 -4.85 -5.31 -6.50
Absolute reduction -0.04 0.00 0.02 0.32 -0.02 0.45 1.63
Relative reduction (%) 0.9 0.0 -0.4 -6.6 0.4 -9.2 -33.6
All stages QALY gap -4.31 -4.35 -4.37 -4.67 -4.33 -4.80 -5.98
Absolute reduction -0.56 -0.52 -0.50 -0.20 -0.54 -0.07 -1.12
Relative reduction (%) 11.5 10.6 10.2 4.0 11.0 1.4 -23.0
All stages plus screening QALY gap -2.13 -2.18 -2.20 -2.50 -2.16 -2.63 -3.81
Absolute reduction -2.73 -2.69 -2.67 -2.37 -2.71 -2.24 -1.06
Relative reduction (%) 56.2 55.3 54.9 48.7 55.7 46.1 21.7
A negative reduction indicates an increase in health gap. Bold type indicates baseline values without interventions.
QALY, quality-adjusted life-year.
Table 4 Results of usual cost-effectiveness analysis and equity-weighted cost-effectiveness analysis
Treatment
Costs (€)
Effects Cost-effectiveness ratio
Normal Equity weighted Normal Equity weighted
75- 75+ 75- 75+ 75- 75+ 75- 75+ 75- 75+
Stage I 10,130 9,672 1.570 0.376 1.925 0.286 6,454 25,754 5,264 33,862
Stage II 10,044 9,570 1.556 0.370 2.016 0.285 6,456 25,889 4,982 33,564
Stage III 10,777 10,305 2.388 0.556 3.325 0.439 4,513 18,537 3,242 23,498
Stage IV 6,250 5,839 0.389 0.084 0.594 0.069 16,054 69,688 10,529 84,455
All stages 9,779 9,320 1.825 0.426 2.505 0.334 5,358 21,895 3,905 27,867
All stages and screening 16,788 17,006 6.896 1.445 8.801 1.126 2,435 11,766 1,908 15,105
576 Baeten et al.
effects (both QALYs and EQALYs) are associated with the sce-
nario that includes screening and treatment of all breast cancer
stages. The screening and treatment of women below 75 years is
the most cost-effective scenario in both the traditional and equity
weighting approach. The costs associated with the scenarios
differ less than €500 between the two groups of women, but the
difference in effects are relatively large in favor of women below
75 years.
In Table 5, all 12 scenarios are characterized using the set of
attributes as described by Baltussen and Niessen [11], and
applied to breast cancer treatment options. The resulting prob-
abilities of selection of each treatment option are given in the
bottom row. The most probable interventions for selection are
the treatment of stage III or the treatment of all stages for women
under the age of 75 (P = 0.821), and the least probable is the
exclusive treatment of stage I breast cancer for elderly women
(P = 0.199). Adding screening in control packages in the two age
groups follows closely. The probabilities also show that selecting
treatment interventions aimed at the group of women below 75
years of age are considered to be more attractive than those that
are aimed at those of 75 and higher, for equity reasons.
Table 6 summarizes the results of the different interventions
in separate composite league tables. Treating women aged below
75 years of age is more attractive than treating women over 75
years of age in all three approaches. In addition, all approaches
except the multicriteria decision analysis rank the extensive
program (i.e., screening with all types treatment) as most
attractive.
Discussion
Interventions aimed at women less than 75 years of age rank
higher in all of the equity-including approaches. Treatment sce-
narios for women of 75 and over lead to larger health disparities
between the two age groups; have lower equity-adjusted CERs;
and are less likely to have a high probability of selection in
applying multiple criteria.
The results of the target group approach can be explained by
the relative high average loss of healthy life-years at breast cancer
diagnoses among ages below 75 in the base-case scenario (i.e., no
treatment for either group). Women that received a diagnosis of
breast cancer aged 80 already have lived 10 more years in good
health than women that received a diagnosis at age 70. There-
fore, any intervention aimed at the disadvantaged group (i.e.,
women of lower ages with breast cancer) in the calculation will
result in positive effects on the distribution of health outcomes
across all ages.
The use of equity weights further increases the attractiveness
of treating women below 75 years of age and those of 75 and
over, as compared with the regular efﬁciency approach. This is
because equity weights are higher for women below 75 years
than for women with higher ages, due to the differences in years
lived in good health and the remaining potential life span.
The multicriteria decision analysis shows that having a
disease at a lower age is an important criterion. There are other
contributing factors as the number of potential beneﬁciaries is
higher, the cost-efﬁciency ratio is lower, and the net individual
health beneﬁts are higher in this age group. Hence, interventions
aimed at women below the age of 75 are more likely to be on the
top of the league table.
Although we adapted the model distinguishing different
breast cancer stages, there are constraints using the present breast
cancer model [17]. Yet we did not incorporate implementation
costs. This may vary by group. In addition, the input data used
for the analysis (i.e., the epidemiological data, equity weights, Ta
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and the coefﬁcients in the multicriteria decision analysis) were
not all gathered in a similar setting. Consequently, the measured
equity impact does not reﬂect true distributional preferences for
a single assessed population. For these reasons, our results should
be used with caution. Nevertheless, the signiﬁcance of this
research does not depend on the exact numbers and position in
the league tables for the selected interventions. Testing and com-
paring the potential and its order of magnitude of the three
existing equity–efﬁciency trade-off applications in health technol-
ogy assessment is the main thrust of our article.
Nevertheless, we consider the preference of targeting women
in lower age group as rather robust in the case of breast cancer
control. The methods applied in this area do not result in large
differences between them. Research that addresses interventions
for different diseases, among more heterogeneous groups, and
distributed differently across age groups, may not show similar
patterns and cross-consistency among the three new league
tables. This could potentially make the selection of a single
equity–efﬁciency trade-off approach a delicate matter.
We deﬁned equity in health in terms of changes of health
outcomes given a particular condition and not in terms of health-
care access or net health gains. We believe that equity consider-
ations should be concerned with the presence, severity, and
duration of illness as well as with longevity and lifetime beneﬁts,
i.e., the fair innings principle. Hence, health should be measured
in terms of disability-adjusted life expectancy, health-adjusted life
expectancy, or lifetime QALYs. These measures combine severity
of illness and the fair innings principle, and may account for the
prevailing concepts of equity [29]. We believe that the three
approaches used in this article all incorporated (some of) these
properties of equity.
Nevertheless, the approaches do not deal with equity in the
same way; they all have their own strengths and weaknesses, and
seem to be more complementary than mutually exclusive. Simply
targeting underprivileged groups is the least comprehensive way
to go about the equity–efﬁciency trade-off as it does not require
any prior data collection on preferences of the general public or
policymakers. In addition, a health gap is an intuitively under-
standable measure of differences in health between groups as well
as the gap-reducing effect of interventions, either in absolute or
relative terms. Nevertheless, targeting speciﬁc groups does not
simultaneously assess the impact that an intervention has on
equity and its cost-effectiveness. This means that the trade-off
between equity and efﬁciency remains implicit, albeit it becomes
less transparent.
Equity weighting explicitly combines those preferences with
associated costs and health effects in an easily understandable
measure: the equity adjusted CER, incorporating the willingness
to give up life-years for equity reasons. This measure can be
interpreted as a regular CER. Although it may be easy to inter-
pret equity weights and equity-weighted outcomes, it may be
difﬁcult to understand in which way equity weights are measured
and calculated.
Multicriteria decision analysis incorporates more aspects of
health interventions than the other two approaches. Nevertheless,
preferences about the relative importance of different criteria are
measured in a different context and may be situation determined.
Another disadvantage of this approach is the large amount of
information that is lost as the performance on each criterion is
categorized, weighted in a single outcome measure, i.e., the prob-
ability of selection. This limits the possibility to distinguish
between different interventions. The number of potential proﬁles
is especially limited if all investigated interventions are aimed at
the same disease and same age group as in our example.
Our study shows that there are some applications of the
equity–efﬁciency trade-off at the disposal of policymakers. These
applications are potentially promising, because they may lead to
better informed and more transparent reimbursement decisions.
Better information can result in a shift from intuition-based
policymaking to more evidence-based policymaking. Various
high-income health-care systems are presently shifting toward a
process of intervention assessment and appraisal. Typically, the
National Institute for Health and Clinical Excellence in the UK
has produced an article on social values. In general, governments
can only accomplish more of health goals if the consequences of
health policies for different goals are known [30].
Nevertheless, increased quantiﬁcation of knowledge on the
impact of health interventions will reduce the autonomy of poli-
cymakers to decide which reimbursement scheme is most attrac-
tive and a priority. This also may result in reluctance from
policymakers toward such explicit applications of the equity–
efﬁciency trade-off. Therefore, it seems most realistic to use the
described incorporation of equitability approaches as a potential
transparent support of policy with regard to accounting for the
equity impact of health interventions.
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